Iovance Biotherapeutics (FRA:2LB) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2LB Iovance Biotherapeutics Inc FRA:2LB
32 GF Score
Price €8.67
! 3 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Iovance Biotherapeutics  (FRA:2LB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Iovance Biotherapeutics Cyclically Adjusted PB Ratio Related Terms


Iovance Biotherapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Cyclically Adjusted PB Ratio Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.32 2.23 2.74 2.32 0.79

Iovance Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.58 0.75 0.91 1.18

FRA:2LB vs ABCL, RCUS, VKTX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:2LB
32GF Score
Iovance Biotherapeutics Inc FRA:2LB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Iovance Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Iovance Biotherapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.421/333.9520*333.9520
=1.421

Current CPI (Jun. 2026) = 333.9520.

Iovance Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.573 241.428 3.559
201612 2.542 241.432 3.516
201703 2.247 243.801 3.078
201706 1.806 244.955 2.462
201709 1.945 246.819 2.632
201712 1.656 246.524 2.243
201803 2.654 249.554 3.552
201806 2.499 251.989 3.312
201809 2.246 252.439 2.971
201812 3.304 251.233 4.392
201903 3.139 254.202 4.124
201906 2.818 256.143 3.674
201909 2.581 256.759 3.357
201912 2.107 256.974 2.738
202003 1.748 258.115 2.262
202006 4.611 257.797 5.973
202009 4.141 260.280 5.313
202012 3.653 260.474 4.683
202103 3.689 264.877 4.651
202106 4.055 271.696 4.984
202109 3.845 274.310 4.681
202112 3.482 278.802 4.171
202203 3.157 287.504 3.667
202206 2.865 296.311 3.229
202209 2.546 296.808 2.865
202212 2.493 296.797 2.805
202303 2.736 301.836 3.027
202306 2.360 305.109 2.583
202309 2.488 307.789 2.699
202312 2.066 306.746 2.249
202403 2.251 312.332 2.407
202406 2.412 314.175 2.564
202409 2.275 315.301 2.410
202412 2.247 315.605 2.378
202503 2.129 319.799 2.223
202506 1.740 322.561 1.801
202509 1.551 324.800 1.595
202512 1.444 324.054 1.488
202603 1.430 330.213 1.446
202606 1.421 333.952 1.421

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
32GF Score

Get the complete analysis for FRA:2LB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.67
Price